ObsEva SA (NASDAQ:OBSV) – Stock analysts at Wedbush issued their FY2025 EPS estimates for ObsEva in a note issued to investors on Tuesday, January 12th. Wedbush analyst L. Moussatos forecasts that the company will post earnings per share of ($0.96) for the year. Wedbush has a “Buy” rating and a $28.00 price target on the stock.
A number of other equities research analysts also recently issued reports on OBSV. JPMorgan Chase & Co. downgraded ObsEva from a “neutral” rating to an “underweight” rating in a research report on Monday, November 9th. SVB Leerink increased their price objective on ObsEva from $4.00 to $5.00 and gave the stock an “outperform” rating in a research report on Tuesday. Zacks Investment Research upgraded ObsEva from a “sell” rating to a “hold” rating in a research report on Tuesday. Finally, HC Wainwright lowered their price objective on ObsEva from $23.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, January 4th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $10.21.
Shares of OBSV stock traded up $0.02 on Thursday, reaching $2.13. The company’s stock had a trading volume of 11,699 shares, compared to its average volume of 1,171,974. The company has a quick ratio of 2.06, a current ratio of 2.06 and a debt-to-equity ratio of 1.14. ObsEva has a 12-month low of $1.63 and a 12-month high of $6.30. The company has a market capitalization of $102.24 million, a P/E ratio of -0.85 and a beta of 1.00. The stock’s 50 day simple moving average is $2.10 and its 200-day simple moving average is $2.55.
ObsEva (NASDAQ:OBSV) last posted its earnings results on Thursday, November 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.15).
A number of institutional investors and hedge funds have recently added to or reduced their stakes in OBSV. Jane Street Group LLC bought a new position in ObsEva in the third quarter valued at $27,000. GSA Capital Partners LLP bought a new position in ObsEva in the third quarter valued at $38,000. Schonfeld Strategic Advisors LLC bought a new position in ObsEva in the third quarter valued at $114,000. State Street Corp bought a new position in ObsEva in the third quarter valued at $124,000. Finally, California Public Employees Retirement System bought a new position in ObsEva in the second quarter valued at $401,000. 49.57% of the stock is currently owned by institutional investors and hedge funds.
ObsEva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.
Further Reading: How to identify percentage decliners
Receive News & Ratings for ObsEva Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ObsEva and related companies with MarketBeat.com’s FREE daily email newsletter.